Treatment with AZD4635 alone and in combination with an anti-PD-L1 mAb was associated with reduction of tumor burden in phase I clinical trials in subjects with refractory solid tumors (18) and is currently entering a phase II study in subjects with metastatic castration-resistant prostate cancer [https://clinicaltrials.gov/ct2/show/NCT04089553]. This evidence concerns the gene CD274 and neoplasm.